semaglutide prediabetes progression to type 2 diabetes trial Efficacy and safety of once-weekly 2·4 mg versus placebo in people with obesity and (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 Prediabetes remission to reduce the

The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major adverse cardiovascular events in overweight and obese adults (Lincoff et al., 2023)

A practical starting point before moving into more targeted therapies

Report any new or worsening mood changes promptly

Read more: To view or add a comment, sign in A new study presented at the European Society of Cardiology Congress 2025, powered by Truveta Data from more than 200,000 patients, found: Early discontinuation was linked to higher cardiovascular risks

If you have an underactive thyroid (hypothyroidism) or an autoimmune condition like Hashimotos thyroiditis, these medications will not replace your need for levothyroxine or address the underlying immune attack on your gland

Colorcon helps companies make the move from injectables to solid dosage forms with confidence